Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tertomotide - KAEL-GemVax

Next Previous
Drug Profile

Tertomotide - KAEL-GemVax

Alternative Names: GV1001®; hTERT RNA vaccine - KAEL-GemVax; LucaVax; RIAVAX; Telomerase peptide vaccine - KAEL-GemVax; TeloVac; Tertomotide HCl

Latest Information Update: 08 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmexa
  • Developer Affitech A/S; Cancer Research UK; KAEL-GemVax; Lytix Biopharma; Norwegian Radium Hospital; Pharmexa
  • Class Alzheimer vaccines; Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic cancer
  • Phase III Benign prostatic hyperplasia
  • Phase II Alzheimer's disease; Colorectal cancer; Non-small cell lung cancer; Progressive supranuclear palsy
  • Phase I/II Malignant melanoma
  • Phase I Neurodegenerative disorders
  • No development reported Solid tumours
  • Discontinued Liver cancer

Most Recent Events

  • 01 Sep 2025 GemVax & Kael completes a phase II trial for Progressive supranuclear palsy in South Korea (SC) (NCT06235775)
  • 25 Aug 2025 GemVax & KAEL completes a phase I trial in Neurodegenerative disorders (In volunteers) in South Korea (SC) (NCT06625710)
  • 29 Oct 2024 Efficacy and adverse event data from a phase IIa trial in Progressive supranuclear palsy released by GemVax & KAEL

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top